Acasti Pharma Inc. (NASDAQ:ACST) could be among the worst stocks to invest in right now as the company shares are trading 3.52% or 0.07 points down from last closing price of $1.99, reaching $1.92 at last check. Any clue why there is so much of action in the ACST stock? The share price has dropped in 4 of the last 5 days and is up 6.42% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 163,417 shares, and in total 1.811 million shares valued at $3.477 million were seen changing hands compared with 1.648 million shares valued at $3.279 million recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the ACST stock.
Acasti Pharma Inc. (ACST) shares have notched a 3-month gain of about 6.42%, but has still advanced 139.21% year to date. By comparison, the stock added 188.41% over the past 12 months, while it jumped 7.57% over the 1 month. The company’s market cap is around $169.8M, with its short interest ratio standing at 0.86%.
In the current trading session for ACST, the stock witnessed two major price actions, it rose to a high of $2 and was down as much as $1.91 at one point. The high recorded is very low when compared to their 52-week high which is $0.62. The 52-week high is now at -34.92 distance from current price. Their recent low of $2.95 represents a 209.68% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ACST is $2.52, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
ACST‘s last price was up 28.69% as compared to the average trading price of 50 days recorded at $1.49 while enlarging the period to 200 trading days, the average closing price was $2. At present, there are 85.33 million in the total number of common shares owned by the public and among those 72 million shares have been available to trade. The percentage of shares being held by the company management was 13.28% while institutions stake was 4.02%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the ACST stock, there is another set of technicals that should be looked into and considered. Its -5.37% decline from moving average of $2.03 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Acasti Pharma Inc. — 5 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $6.94 on shares of Acasti Pharma Inc. (NASDAQ:ACST), which corresponds to 261.33% upside potential than its current market price of $1.92 and implies potential despite the recent drop in the price. However, their current target price has fallen from $6.94 a month ago and is down handily from the consensus target of $6.94 a quarter ago.